Home > Boards > US Listed > Biotechs > Regeneron Pharmaceuticals (REGN)

$REGN recent news/filings

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
stocktrademan Member Profile
 
Followed By 457
Posts 9,985
Boards Moderated 1
Alias Born 04/28/14
160x600 placeholder
Current Report Filing (8-k) Edgar (US Regulatory) - 4/7/2020 6:46:48 AM
Correction to Sanofi Article Dow Jones News - 4/7/2020 4:27:00 AM
Sanofi Finalizes Praulent Restructuring With Regeneron Dow Jones News - 4/7/2020 2:09:00 AM
Regeneron Finalizes Praluent Agreement Restructuring Dow Jones News - 4/6/2020 7:42:00 PM
Regeneron Finalizes Praluent® (alirocumab) Restructuring and Updates Accounting Presentation PR Newswire (US) - 4/6/2020 5:00:00 PM
Inside the Race to Find a Coronavirus Cure Dow Jones News - 4/6/2020 12:41:00 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/3/2020 4:51:31 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/3/2020 4:50:43 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/3/2020 4:09:01 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/3/2020 4:06:31 PM
Sanofi CEO: 'The One-Meeting Trip Will Disappear' Dow Jones News - 4/3/2020 9:29:00 AM
Recession Blue-Chips' Led the Way in Another Turbulent Week in Markets Dow Jones News - 4/3/2020 7:29:00 AM
Dupixent® (dupilumab) Phase 3 Data at Revolutionizing Atopic Dermatitis Conference Show Significant Improvement in Severe At... PR Newswire (US) - 4/3/2020 12:59:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/1/2020 6:50:29 PM
Regeneron Announces American College of Cardiology Presentation of Positive Phase 3 Evinacumab Results in Patients with Sever... PR Newswire (US) - 3/30/2020 11:46:00 AM
First patient outside U.S. treated in global Kevzara® (sarilumab) clinical trial program for patients with severe COVID-19 PR Newswire (US) - 3/30/2020 12:59:00 AM
Regeneron Announces Important Advances in Novel COVID-19 Antibody Program PR Newswire (US) - 3/17/2020 7:00:00 AM
Regeneron and Sanofi Start U.S. Studies Assessing Arthritis Drug As Coronavirus Treatment Dow Jones News - 3/16/2020 11:10:00 AM
Regeneron, Sanofi Start Trials for Drug to Treat Covid-19 Dow Jones News - 3/16/2020 8:57:00 AM
Regeneron and Sanofi Begin Global Kevzara® (sarilumab) Clinical Trial Program in Patients with Severe COVID-19 PR Newswire (US) - 3/16/2020 8:09:00 AM
Sanofi and Regeneron begin global Kevzara® (sarilumab) clinical trial program in patients with severe COVID-19 PR Newswire (US) - 3/16/2020 8:00:00 AM
It's a Tough Time to Be in the C-Suite, Good Time to Be in a Gas Field Dow Jones News - 3/13/2020 7:29:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 3/11/2020 5:00:59 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 3/11/2020 4:07:23 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 3/11/2020 4:06:26 PM
stocktrademan   Monday, 05/18/15 05:08:21 PM
Re: None
Post # of 141 
$REGN recent news/filings

bullish
triangle resistance breakout
macd crossup
in the top bollinger band area

## source: finance.yahoo.com

Mon, 18 May 2015 20:21:44 GMT ~ Healthcare Winners and Losers: May 18, 2015


read full: http://finance.yahoo.com/video/healthcare-winners-losers-may-6-202126519.html
*********************************************************

Mon, 18 May 2015 16:51:27 GMT ~ Sanofi and Regeneron Announce Positive Pivotal Phase 2b Dupilumab Data in Asthma Presented at the American Thoracic Society 2015 International Conference

[at noodls] - - Phase 3 Clinical Trial in Uncontrolled Persistent Asthma Underway - Paris and Tarrytown, NY - May 18, 2015-Sanofi and Regeneron Pharmaceuticals, Inc. today shared additional positive results from an ...

read full: http://www.noodls.com/view/815ABAFFD2360AAE5EB82D15F0A60C9682DE544F
*********************************************************

Mon, 18 May 2015 16:31:00 GMT ~ 12:31 pm Regeneron Pharms and Sanofi (SNY) announce positive results from an interim analysis of a pivotal Phase 2b study of dupilumab in adult patients with moderate-to-severe asthma


read full: http://finance.yahoo.com/news/inplay-briefing-com-055139997.html#regn
*********************************************************

Mon, 18 May 2015 16:30:00 GMT ~ Regeneron and Sanofi Announce Positive Pivotal Phase 2b Dupilumab Data in Asthma Presented at the American Thoracic Society 2015 International Conference

[PR Newswire] - TARRYTOWN, N.Y. and PARIS, May 18, 2015 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi today shared positive results from an interim analysis of a pivotal Phase 2b study of dupilumab in adult patients with moderate-to-severe asthma, who are uncontrolled despite treatment with inhaled corticosteroids and long-acting beta agonists (ICS/LABA). As previously reported, the study met its primary endpoint of improving lung function in asthma patients with high blood eosinophil counts (HEos, greater than or equal to 300 eosinophilic cells/microliter). Such high counts are thought to be a marker for patients more likely to have "atopic" or "allergic" asthma. New data presented on secondary endpoints at the American Thoracic Society 2015 International Conference included positive results in study patients with low blood eosinophil counts (LEos, less than 300 eosinophilic cells/microliter), who are thought to be less likely to suffer from "allergic" asthma and thus less likely to respond to TH2 targeted therapies.

read full: http://finance.yahoo.com/news/regeneron-sanofi-announce-positive-pivotal-163000724.html
*********************************************************

Mon, 18 May 2015 15:33:00 GMT ~ Regeneron: Why It's Heading to $550


read full: http://blogs.barrons.com/stockstowatchtoday/2015/05/18/regeneron-why-its-heading-to-550/?mod=yahoobarrons&ru=yahoo
*********************************************************

$REGN charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com



$REGN company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/REGN/company-info
Ticker: $REGN
OTC Market Place: Not Available
CIK code: 0000872589
Company name: Regeneron Pharmaceuticals, Inc.
Incorporated In: NY, USA

$REGN share structure

## source: otcmarkets.com

Market Value: $49,539,462,703 a/o May 15, 2015
Shares Outstanding: 101,305,623 a/o Apr 16, 2015
Float: Not Available
Authorized Shares: Not Available
Par Value: 0.001

$REGN extra dd links

Company name: Regeneron Pharmaceuticals, Inc.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/REGN/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/REGN/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=REGN+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=REGN+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=REGN+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/REGN/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/REGN/news - http://finance.yahoo.com/q/h?s=REGN+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/REGN/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/REGN/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/REGN/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/REGN/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/REGN/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/REGN/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/REGN/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/REGN/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=REGN+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/REGN
DTCC (dtcc.com): http://search2.dtcc.com/?q=Regeneron+Pharmaceuticals%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Regeneron+Pharmaceuticals%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Regeneron+Pharmaceuticals%2C+Inc.&x=0&y=0

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/REGN/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/REGN
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/REGN/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/REGN/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/REGN/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000872589&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/REGN/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/REGN/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/REGN/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/REGN/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=REGN&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=REGN
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/REGN/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=REGN+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=REGN+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=REGN
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=REGN
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=REGN+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/REGN/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=REGN+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/REGN.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=REGN
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/REGN/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/REGN/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/REGN/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/REGN/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/REGN
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/REGN
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/REGN:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=REGN
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=REGN



$REGN DD Notes ~ http://www.ddnotesmaker.com/REGN

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist